A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT ID: NCT07300150
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
195 participants
INTERVENTIONAL
2025-11-21
2028-10-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1a: Dose Escalation
Participants with solid tumors with any KRAS mutation or amplified WT KRAS will receive PT0511 infusion, intravenously (IV), until disease progression or intolerance.
PT0511
Intravenous infusion.
Part 1b: Dose Expansion: Tumor type 1
Participants with tumor type 1 will receive PT0511 infusion until disease progression or intolerance. Recommended dose or doses for expansion for Part 1b will be determined based on the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) data for PT0511 established in Part 1a.
PT0511
Intravenous infusion.
Part 1b: Dose Expansion: Tumor type 2
Participants with tumor type 2 will receive PT0511 infusion in combination with cetuximab infusion, until disease progression or intolerance. Recommended dose or doses for expansion for Part 1b will be determined based on the safety, tolerability, PK and PD data for PT0511 established in Part 1a.
PT0511
Intravenous infusion.
Cetuximab
Intravenous infusion.
Part 1b: Dose Expansion: Tumor type 3
Participants with tumor type 3 will receive PT0511 infusion until disease progression or intolerance. Recommended dose or doses for expansion for Part 1b will be determined based on the safety, tolerability, PK and PD data for PT0511 established in Part 1a.
PT0511
Intravenous infusion.
Part 1b: Dose Expansion: Tumor type 4
Participants with tumor type 4 will receive PT0511 infusion until disease progression or intolerance. Recommended dose or doses for expansion for Part 1b will be determined based on the safety, tolerability, PK and PD data for PT0511 established in Part 1a.
PT0511
Intravenous infusion.
Part 1b: Dose Expansion: Tumor type 5
Participants with tumor type 5 will receive PT0511 infusion until disease progression or intolerance. Recommended dose or doses for expansion for Part 1b will be determined based on the safety, tolerability, PK and PD data for PT0511 established in Part 1a.
PT0511
Intravenous infusion.
Part 1b: Dose Expansion: Tumor type 6
Participants with tumor type 6 will receive PT0511 infusion until disease progression or intolerance. Recommended dose or doses for expansion for Part 1b will be determined based on the safety, tolerability, PK and PD data for PT0511 established in Part 1a.
PT0511
Intravenous infusion.
Part 1b: Dose Expansion: Tumor type 7
Participants with tumor type 7 will receive PT0511 infusion until disease progression or intolerance. Recommended dose or doses for expansion for Part 1b will be determined based on the safety, tolerability, PK and PD data for PT0511 established in Part 1a.
PT0511
Intravenous infusion.
Part 1b: Dose Expansion: Tumor type 8
Participants with tumor type 8 will receive PT0511 infusion until disease progression or intolerance. Recommended dose or doses for expansion for Part 1b will be determined based on the safety, tolerability, PK and PD data for PT0511 established in Part 1a.
PT0511
Intravenous infusion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PT0511
Intravenous infusion.
Cetuximab
Intravenous infusion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically or cytologically confirmed advanced or metastatic solid malignancy.
3. Participant has a pathologically documented, locally advanced or metastatic malignancy with any KRAS mutation or wild-type (WT) KRAS amplification identified through molecular testing using a Clinical Laboratory Improvement Amendments (CLIA) certified, validated institutional or commercial test.
• Participant must have received at least 1 and no more than 4 prior systemic therapies or be intolerant or ineligible for available therapies known to provide clinical benefit.
4. Measurable disease (RECIST 1.1 Criteria).
5. ECOG Performance Status 0 or 1.
6. Willingness to avoid pregnancy or fathering children screening through 90 days after the last dose of study treatment.
Exclusion Criteria
1. Active brain metastasis or carcinomatous meningitis. If participants have had brain metastases resected or have received radiation therapy, they may be eligible if: (1) study treatment begins at least 4 weeks from the end of brain-specific therapy, (2) residual neurological symptoms Grade \<=2, (3) currently on stable doses of corticosteroids, and (4) pre-study brain MRI documents no new/worsening brain lesions.
2. History of any other malignancy within the past 2 years, except:
* Malignancy treated with curative intent and with no known active disease present \>=2 years before enrolment and felt to be at low risk for recurrence by the investigator.
* Basal or squamous cell carcinoma of the skin, in situ cervical cancer, early -stage endometrial cancer that has been definitively treated, superficial bladder cancer, Gleason 6/7 treated prostate cancer, and ductal carcinoma in situ or lobular carcinoma in situ of the breast.
Prior Cancer Therapy
3. Unresolved toxicities from prior anti-cancer therapies. Participants with prior endocrine replacement therapies are eligible for entry even if administered to treat endocrine deficiency due to the prior anti-cancer therapy.
4. Concurrent participation in another interventional clinical study.
5. Treatment with anticancer medications or investigational drugs within the following intervals before the first administration of study drug:
* At least 14 days for chemotherapy or targeted small-molecule therapy.
* At least 28 days for a prior monoclonal antibody.
* At least 28 days or 5 half-lives (whichever is longer) for all other investigational study drugs or devices. For drugs with very long half-lives, participants may be allowed to enroll prior to 5 half-lives at the discretion of the investigator in discussion with the medical monitor.
* Note: Concurrent hormonal therapy for prostate or breast cancer is allowable
6. Prior treatment with a KRAS/RAS degrader.
Medical History
7. Significant cardiovascular disease within 6 months of starting study therapy.
8. Active infection requiring antibiotics within 7 days of study treatment.
9. Known HIV infection with a CD4+ T-cell count \<200 cells/mcL and/or a detectable viral load per parameters of assay and/or on an anti-retroviral regimen containing a strong or moderate CYP3A4/5 inhibitor or inducer and/or on a new anti-retroviral regimen for less than 28 days prior to the initiation of study treatment.
10. Known history of drug-induced liver injury; primary biliary cirrhosis; or ongoing extrahepatic obstruction caused by stones, cirrhosis of the liver, or portal hypertension.
11. Major surgery within 4 weeks of the start of study therapy or postoperative complications preventing the participant from adhering to protocol assessments and procedures.
12. Known hypersensitivity to any of the products to be administered during dosing.
13. Any disease or disorder that, in the opinion of the investigator, may compromise the ability of the participant to provide written informed consent and/or to comply with all required study procedures.
Medications
14. Part 1a (Dose escalation): Use of a strong or moderate CYP3A4/5 inhibitor or inducer, Use of a strong P-gp inhibitor or inducer.
Organ Function
15. Participants with laboratory values indicating inadequate hematology, hepatic, or renal function.
Diagnostic Assessments
16. Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG.
17. Baseline QT interval corrected for heart rate using Fridericia's formula (QTcF) \>=470 msec
18. Female participants of childbearing age with a positive urine or serum test within 7 days of study start or confirmation from Ob/Gyn that any positive bHCG test is not representative of an ongoing pregnancy.
19. Women who are lactating/breast feeding or who plan to breastfeed while on study through 28 days after receiving the last dose of study drug.
20. Active HBV infection. Participants with resolved infection or who are on Stable antiviral therapy are eligible.
21. Active HCV infection. Participants who have completed definitive antiviral therapy with post treatment confirmation of eradication are eligible.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PAQ Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dana-Farber/Massachusetts General Hospital, Inc
Boston, Massachusetts, United States
New Experimental Therapeutics of San Antonio LLC
San Antonio, Texas, United States
START - South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, United States
START Mountain Region
West Valley City, Utah, United States
NEXT Virginia
Fairfax, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Leon Pappas
Role: primary
Ildefonso Ismael Rodriguez Rivera
Role: primary
Drew Rasco
Role: primary
William McKean
Role: primary
Alexander Spira
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PT0511-101
Identifier Type: -
Identifier Source: org_study_id